Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL4101 Target Snapshot

cAMP-dependent protein kinase catalytic subunit alpha · SINGLE PROTEIN · Homo sapiens

2,608Compounds
361Assays
4Approved Drugs
1,779.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-13

Protein identity stays anchored to UniProt P17612. Use UniProt P17612 as the stable identity anchor, then attach disease evidence before program review.

Review focus
Protein anchor ready

Use UniProt P17612 as the stable identity anchor, then attach disease evidence before program review.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-13
Open source guide
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats cAMP-dependent protein kinase catalytic subunit alpha as ChEMBL target CHEMBL4101, mapped to UniProt P17612. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
cAMP-dependent protein kinase catalytic subunit alpha
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
ChEMBL target ID
CHEMBL4101
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
P17612
cAMP-dependent protein kinase catalytic subunit alpha
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether cAMP-dependent protein kinase catalytic subunit alpha is the right protein anchor across sources, using UniProt P17612 as the stable mapping.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need the strongest disease program and evidence level in one place.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein LabelcAMP-dependent protein kinase catalytic subunit alpha
UniProt AccessionP17612
Component TypeProtein
Sequence Length351 aa

cAMP-dependent protein kinase catalytic subunit alpha

Source · UniProt accession via ChEMBL component mapping
Review Cue

How to read this target

Review this target as cAMP-dependent protein kinase catalytic subunit alpha, mapped to UniProt P17612. Sequence length is 351 aa.

Mapped IDP17612
Review namecAMP-dependent protein kinase catalytic subunit alpha
OrganismHomo sapiens
Clinical Profile

Clinical Phase Distribution

4
Approved
7
Phase III
8
Phase II
9
Phase I
Assay Mix

Activity Type Distribution

IC50183.0
KI1,203.0
KD393.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL5201435 10.72 Kd 0.019 Preclinical
CHEMBL5179794 10.64 Ki 0.023 Preclinical
CHEMBL5185265 10.38 Kd 0.042 Preclinical
CHEMBL524516 9.3 Kd 0.5 Preclinical
CHEMBL5174535 9.2 Ki 0.63 Preclinical
CHEMBL5189362 9.2 Kd 0.63 Preclinical
CHEMBL1980995 9.1 Ki 0.7943 Preclinical
CHEMBL388978 9.03 IC50 0.935 Preclinical
CHEMBL1980407 8.9 Ki 1.259 Preclinical
CHEMBL498924 8.74 Kd 1.8 Preclinical
Distribution

pChEMBL Value Distribution

73
5.0
110
5.5
131
6.0
97
6.5
68
7.0
49
7.5
27
8.0
6
8.5
5
9.0
0
9.5
pChEMBL
Approved Drugs

Approved Drugs

CAPIVASERTIB
CHEMBL2325741
Approved 2023
MIDOSTAURIN
CHEMBL608533
Approved 2017
PONATINIB
CHEMBL1171837
Approved 2012
Assay Landscape

Assay Landscape

361
Total Assays
392
Tested Compounds
3
Assay Types
Binding — 359 assays, 181 compounds
BAO Format Assays Compounds Avg pChEMBL
single protein format 265 156 6.4
assay format 66 14 6.5
cell-based format 14 1
subcellular format 13 10 6.5
biochemical format 1 0
ADME — 1 assays, 0 compounds
BAO Format Assays Compounds Avg pChEMBL
cell-based format 1 0
Functional — 1 assays, 392 compounds
BAO Format Assays Compounds Avg pChEMBL
assay format 1 392 6.3

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine